NL-OMON52981已完成不适用
MEDIASTINAL STAGING OF NON SMALL CELL LUNG CANCER BY ENDOBRONCHIAL AND ENDOSCOPIC ULTRASONOGRAPHY WITH OR WITHOUT ADDITIONAL SURGICAL MEDIASTINOSCOPY (MEDIASTrial) - MEDIASTrial
Maxima Medisch Centrum0 个研究点目标入组 356 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 356
研究概览
简要总结
Trial is onging in other countries
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients with (suspected) NSCLC without distant metastases and suspected
- •metastatic nodal spread on PET or CT scan; or a non PET-avid or centrally
- •located tumour or a peripheral tumour >3 centimeters diameter. Previous
- •EBUS/EUS has shown negative biopsy results.
排除标准
- •Not eligible are patients with: a) highly suspected bulky mediastinal nodal
- •disease; b) high suspicion of single level N2-3 metastasis defined by specific
- •PET and EBUS/EUS characteristics; c) suspected non-resectable N2 disease; d)
- •insufficient comprehension of the dutch language.
研究者
相似试验
已完成
3 期
ong-term treatment for cancer patients with deep vein thrombosis or pulmonary embolism - a randomized open label study1002765510014523venous thrombosis / clotNL-OMON39493Academisch Medisch Centrum10
已完成
不适用
Selecting cancer patients for treatment using Tumor Organoids, the SENSOR studycolon cancerColorectal cancerlung cancernon-small cell lung cancerNL-OMON46891ederlands Kanker Instituut61
已完成
2 期
Mesenchymal stromal cells for treatment of drug resistant pediatric Juvenile idiopathic arthritis1000381610023213juvenile idiopathic arthritisNL-OMON39754niversitair Medisch Centrum Utrecht6
已完成
3 期
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer - Cachexia (NSCLC-C): An Extension Study;(ROMANA-3)cachexiewasting syndroom1000301810027656NL-OMON38190Helsinn Therapeutics (U.S.), Inc1
已完成
3 期
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer - Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients with NSCLC-Ccachexiawasting syndroom1000301810027656NL-OMON37977Helsinn Therapeutics (U.S.), Inc2